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BCG vaccination status may predict sputum
conversion in patients with pulmonary tuberculosis:
a new consideration for an old vaccine?
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ABSTRACT
Background Failure to convert (persistent sputum and/or
culture positivity) while on antituberculosis (anti-TB)
treatment at the end of the second month of anti-TB
therapy has been reported to be a predictor of treatment
failure. Factors that could be associated with persistent
bacillary positivity at the end of the second month after
initiation of anti-TB treatment were assessed.
Methods A prospective cohort study was conducted in
754 patients with sputum culture positive pulmonary TB
in Mwanza, Tanzania. Information on social demographic
characteristics, anthropometric measurements, BCG scar
status, HIV status, CD4+ count, white blood cell count,
haemoglobin and sputum culture status was obtained.
Results Factors associated with sputum culture non-
conversion at the end of the second month of anti-TB
treatment were initial acid-fast bacilli (AFB) culture
grading of 3+ (OR 5.70, 95% CI 1.34 to 24.31, p¼0.02)
and absence of a BCG scar (OR 3.35, 95% CI 1.48 to
7.58, p¼0.004).
Conclusion Patients with pulmonary TB with no BCG
scar and high initial AFB sputum intensity are at risk of
remaining sputum culture positive at the end of the
second month of anti-TB treatment. These findings
reflect a beneficial role for BCG vaccination on sputum
conversion which should also be examined in large
studies in other areas. The finding of a beneficial role for
BCG vaccination on the treatment of pulmonary TB is
important for TB control and vaccination programmes.
INTRODUCTION
Tuberculosis (TB) remains one of the major public
health problems worldwide and represents a major
challenge to health systems in the 21st century.
The total numbers of new TB cases is rising, espe-
cially in Africa, South-East Asia and the Western
Paciﬁc region. These regions contributed 83% of the
total TB cases notiﬁed globally in 2006.1 Tanzania
ranks 14th among the 22 countries, with the
highest TB burden worldwide and sixth in Africa.1
Bacillus Calmette-Guérin (BCG) is still the only
available vaccine for combating TB worldwide. The
BCG vaccine was initially used in humans in 1921
as a disease-modifying agent before the era of
antibiotics and was introduced for protection
against TB disease.2 In 2002 the BCG vaccine was
estimated to have been administered to more than
100 million infants worldwide, covering 76% of the
total 130 million infants globally.3 In sub-Saharan
Africa, BCG is given as a routine to all infants at
birth or at ﬁrst contact with health facilities.4 The
role of BCG vaccine in protecting against TB has
been reported to vary, being more effective in chil-
dren with severe forms of TB (meningitis or miliary
disease).3 Meta-analysis studies show that the BCG
vaccine confers 73% protection against TB menin-
gitis and 77% against miliary forms of TB.5 6
However, the extent to which BCG vaccination
confers protection against adolescent and adult TB
is under debate.3 Failure to convert while on anti-
TB treatment at the end of the second month has
been reported to be a predictor of treatment
failure.7 8 Previous studies have identiﬁed factors
such as pretreatment high sputum acid-fast bacilli
(AFB) smear and sputum culture grading, gender,
smoking and age as potential predictors of sputum
conversion.8e10 However, little is known about
factors that may be associated with persistent
sputum AFB positivity in Tanzania. Thus, factors
that could be associated with sputum non-conver-
sion at the end of the 2 months after initiation of
anti-TB treatment were assessed.
MATERIALS AND METHODS
Study population
The study was conducted in Tanzania in the city of
Mwanza which comprises two districts, Ilemera
and Nyamagana. Mwanza city is divided by the
National Tuberculosis and Leprosy Programme
(NTLP) into three operating TB districts. Four
health facilities (two hospitals and two health
centres) served as recruitment centres. All patients
diagnosed with sputum smear positive pulmonary
TB (PTB) recruited from the three NTLP districts
and attending the four major health facilities from
April 2006 to October 2008 in Mwanza city were
considered for recruitment.
Inclusion and exclusion criteria
Patients with sputum smear positive PTB aged
$15 years recruited at the local health facilities and
conﬁrmed as sputum culture positive at the Zonal
Reference Laboratory were included in the study.
Pregnant women, patients with terminal illness
(from TB or any other serious disease unlikely to
survive more than 48 h), non-residents (patients
who would not stay in the study area for the entire
period of 6 months of anti-TB treatment) and
patients not willing to participate were not
considered for enrolment.
Patient enrolment
Patients diagnosed as sputum smear positive by
microscopy using ZiehleNeelsen (ZN) staining at
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the ﬁrst visit to a diagnostic health facility were referred to any
of the four main recruitment health facilities. Patients were
provided with information on the study and those who were
eligible were asked for oral and written consent. Those who
consented and for whom one or both spot and next day early
morning sputum samples were ZN smear microscopy positive
were requested to provide an additional early morning sputum
specimen. Smear microscopy examination was performed using
Auramine O staining and culture using LowensteineJensen (LJ)
solid media. The LJ tubes were incubated for 8 weeks
before concluding that the samples were culture negative.
Sputum results for AFB were graded according to the NTLP
recommendations.11
Data collection and laboratory procedures
Information on the participants was collected using structured
questionnaires at the ﬁrst visit before initiation of anti-TB
treatment. Information on social demographics, medical history,
smoking history and anthropometric measurements (height and
weight) was ascertained at baseline. Patient weight and height
were measured using a digital weighing scale and height board,
respectively. Documentation on the presence or absence of BCG
scars for each patient was performed by a directly observed
treatment nurse (DOT) at the TB clinic. Conﬁrmation of the
presence of a BCG scar was done by a study team member by
counterchecking on the patient’s TB clinic card in order to
minimise the possibility of an observation bias. The presence of
a BCG scar was regarded as evidence of BCG vaccination. If the
presence of a scar was in doubt it was recorded as absent. HIV
counselling and testing was undertaken for all recruited partici-
pants. Venous blood (15ml) was drawn from each participant for
HIV testing, total lymphocyte count and CD4 cell counts.
Ethylene diaminetetra-acetic acid tubes were used to collect blood
for haemoglobin, white blood cell counts and CD4 counts. HIV
testing and other blood parameters were performed on the same
day as collection at the National Institute for Medical Research
Laboratory, Mwanza, Tanzania. HIV testing was done using two
different rapid antibody tests: Determine HIV-1/2 (Inverness
Medical Japan, Abbot, Japan) and Capillus HIV-1/2 (Trinity
Biotech, Ireland). Discordant samples were tested using Uniform
II Vironostika-HIV Ag/Ab Micro-Elisa system (Biomerieux BV,
The Netherlands). CD4+ counts were performed using a Partec
Cyﬂow counter machine (Partec GmbH, Münster, Germany).
Total lymphocyte counts were determined manually.
Follow-up
All patients with PTB who were diagnosed as sputum smear
positive and/or culture positive were initiated on anti-TB
treatment that was provided under the directly observed treat-
ment short course strategy for a duration of 6 months. Drugs
were given in a ﬁxed dose combination of four drugs (rifampicin,
isoniazid, pyrazinamide and ethambutol) during the ﬁrst
2 months of intensive phase and two drugs in a ﬁxed dose
combination (rifampicin and isoniazid) during the 4 months of
the continuation phase.11 Patients were then followed up by
sputum culture examination at the end of 2 months after anti-
TB treatment.
Statistical analysis
The data were analysed using Stata IC Version 10.1 (StataCorp,
College Station, Texas, USA). The outcome of interest was
culture non-conversion at the end of the second month of
treatment. To identify predictors of non-conversion, the
proportions of non-converters were compared between
categories of potential predictor variables using the c2 test.
Potential predictors considered were age, sex, smoking, initial
culture grading, presence of BCG scar, HIV status, CD4 count,
anaemia and body mass index (BMI). Logistic regression analysis
was done to estimate the relationship between potential
predictors and culture non-conversion, and crude odds ratios as
well as age- and sex-adjusted odds ratios were estimated. A ﬁnal
multivariable logistic regression analysis was performed with all
the predictors with p<0.10 in the age- and sex-adjusted analyses
and with adjustment for other confounders. Continuous vari-
ables were categorised using conventional cut-off points.
Goodness of ﬁt comparisons were done to ensure that the
categorisations of the continuous variables were appropriate.
Tests for interaction between all variables in the ﬁnal model and
HIV status on sputum non-conversion were carried out. p Values
<0.05 were considered to indicate statistical signiﬁcance.
RESULTS
A total of 842 patients with smear positive PTB met the study
criteria for this cohort from April 2006 to October 2008, of
which 754 were enrolled based on a positive culture at baseline.
Of these, 329 (43.6%) were HIV positive. The culture contam-
ination rate at baseline was 4.3%. The majority of recruited
patients were new TB cases (92.3%). Of the 754 patients who
were sputum culture positive at baseline, 208 were excluded
(174 failed to return at the end of the intensive phase or came
much later than the scheduled 2-month visit, 7 died and 27 had
contaminated sputum culture results, ﬁgure 1). When compared
with those patients who remained in the study, the drop-outs
did not differ in their BCG scar status.
Table 1 summarises the background characteristics of the
recruited patients. Their mean (SD) age was 34.5 (11.7) years. Of
the 754 patients recruited, 546 (72%) presented at the end of the
second month of the intensive phase of treatment. The sputum
culture non-conversion rate at the end of the second month after
anti-TB treatment for these 546 patients was 5.5% (table 2). A
total of 3.5% of the women and 6.7% of the men (p¼0.12)
remained sputum culture positive at the end of the second
month of anti-TB treatment. Of the 546 patients who were AFB
culture positive at baseline and followed up at the end of the
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329; HIV+ 
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nd
month
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Figure 1 Flow chart for patients with culture positive pulmonary
tuberculosis (PTB) at baseline followed for sputum culture conversion at
the end of the second month of the intensive phase of treatment.
Thorax 2010;65:1072e1076. doi:10.1136/thx.2010.134767 1073
Tuberculosis
second month of the intensive phase, there was no observed
difference between sputum culture non-conversion among
patients categorised by age, smoking, CD4 count, HIV status,
haemoglobin levels and BMI (table 2). However, a higher
proportion of patients who had a pretreatment AFB culture
grading of 3+ failed to convert compared with patients with
a baseline sputum culture grading of #2+ (7.2% and 1.3%,
respectively; p¼0.006). For patients who did not have a BCG
scar, 11.6% remained sputum culture positive compared with
4.1% of those who had a BCG scar (p¼0.003, table 2).
Logistic regression was performed to identify factors that
were independently associated with sputum culture non-
conversion at the end of the second month after anti-TB treat-
ment. The absence of a BCG scar (OR 3.35, 95% CI 1.48 to 7.58,
p¼0.004) and initial AFB culture grading of 3+ (OR 5.70, 95%
CI 1.34 to 24.31, p¼0.02) remained signiﬁcantly associated with
persistent sputum culture positivity (table 2).
In the multivariate regression model, factors that remained
independently associated with culture non-conversion at
2 months after being adjusted for age and sex included an initial
AFB culture grading of 3+, which was associated with an almost
ﬁvefold increased risk of sputum culture conversion failure (OR
5.24, 95% CI 1.22 to 22.48, p¼0.03) and absence of a BCG scar,
which was associated with a threefold increased risk (OR 3.18,
95% CI 1.39 to 7.26, p¼0.006) of sputum culture conversion
failure. There was no confounding or interaction for the factors
that remained signiﬁcant.
DISCUSSION
Sputum smear/culture conversion at the end of the second
month of anti-TB treatment has been considered as an impor-
tant indicator for the success of TB treatment.7 8 12 In the
present study we observed an overall non-conversion rate
(2 months after anti-TB treatment) of 5.5% for the 546 patients
who were initially sputum culture positive. For the 30 patients
who did not convert at 2 months, 29 were sputum smear
negative (ie, they were cured by standard anti-TB treatment)
while one patient remained sputum smear positive at 5 months
after anti-TB treatment (data not shown). Patients with TB who
had a high initial (pretreatment) culture grading and an absence
of a BCG scar were more likely to have persistent sputum
culture positivity at the end of the second month of anti-TB
treatment. Previous studies have shown that sputum non-
conversion at the end of the intensive phase of anti-TB treat-
ment has been associated with high initial smear/culture
grading, male gender and low BMI.7e9 12 13 Patients with
numerous AFB in the sputum reﬂect the high numbers of bacilli
in the lung, with a corresponding increase in cavity formation.
Thus, delayed sputum conversion in patients with high initial
bacillary loads in the sputum is not surprising.13 14 Interaction
between malnutrition and TB is associated with complex
mechanisms. BMI is an indicator of nutritional status. Both
micronutrient and macronutrient deﬁciency can inﬂuence
susceptibility to TB. Severe malnutrition has a profound effect
on cell-mediated immunity.15 In this study patients with PTB
with a BMI <17.0 kg/m2 and 17.0e18.5 kg/m2 had a sputum
culture non-conversion rate of 5.4% and 8.2%, respectively, at
the end of the second month of the intensive phase of treat-
ment. Patients with a BMI of <18.5 kg/m2 were more likely to
remain sputum culture positive than those with a BMI of
>18.5 kg/m2, although the results were not signiﬁcant.
Our study shows that there was no signiﬁcant difference in
conversion rates among patients with TB co-infected with HIV
and those not infected with HIV. The sputum culture conver-
sion rate for HIV negative patients was 93.9% compared with
95.4% for those who were HIV positive. CD4+ counts, despite
playing a role in immunity, did not signiﬁcantly inﬂuence the
sputum conversion rate. In agreement with previous studies,15
there was no difference in sputum conversion rates with
different CD4+ counts. Patients with CD4+ counts of #200,
201e350 and >350 had sputum culture conversion rates of
95.9%, 92.7% and 94.8%, respectively. At the 2-month observa-
tion period the mean number of days in anti-TB drug compli-
ance among converters was 57 days compared with 59 days for
non-converters (p¼0.16), indicating that there was no difference
in treatment compliance between the two groups (data not
shown).
Interestingly and, to our knowledge, reported for the ﬁrst
time, the presence of a BCG scar was signiﬁcantly associated
with sputum culture conversion (p¼0.006) at the end of the
second month of the intensive phase of anti-TB treatment. The
dose of BCG and the route of administration are important for
scar development. In Tanzania, BCG vaccine is given to all
infants at birth intradermally in the upper part of the right arm
at a dose of 0.05 ml and is included in the expanded programme
of immunisation. The presence of a scar on the appropriate area
of the arm has been considered evidence of prior BCG vaccina-
tion. However, BCG scars may be difﬁcult to assess. Moreover,
Table 1 Background characteristics for 754 patients with sputum
culture positive pulmonary tuberculosis*
Age (N¼754) 34.6 (11.7)
15e24 years 18.4 (139)
25e34 years 38.1 (287)
35e44 years 25.1 (189)
$45 years 18.4 (139)
Sex (N¼754)
Female 37.5 (283)
Male 62.5 (471)
Smoking (N¼751)
Never smoker 66.8 (502)
Past smoker 9.9 (74)
Current smoker 23.3 (175)
Culture grading (N¼754)y
1+ 17.1 (129)
2+ 14.3 (108)
3+ 68.6 (517)
BCG scar (N¼747)
Present 81.4 (608)
Not present 18.6 (139)
CD4 count (N¼753) 354 (210; 572)
<200 cells/ml 23.0 (173)
201e350 cells/ml 26.6 (200)
>351 cells/ml 50.4 (380)
HIV status (N¼754)
Negative 56.4 (425)
Positive 43.6 (329)
Haemoglobin (g/dl) (N¼753)z 10.6 (2.4)
No anaemia 19.3 (145)
Anaemia 80.7 (608)
Body mass index (N¼753) 18.4 (2.7)
$18.5 kg/m2 41.4 (312)
17.0e18.5 kg/m2 26.4 (199)
<17.0 kg/m2 32.1 (242)
*Data are mean (SD), median (IQR) or % (n).
yCulture grading defined as follows: 1+, 1e100 colonies; 2+, >100 colonies, 3+,
confluent colonies.
zAnaemia defined as haemoglobin <12.0 g/dl for women and <13.0 g/dl for men.
BCG, Bacillus Calmette-Gue´rin.
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as shown by Fine et al,16 the less clear the mark or scar, the
greater the potential for subjective bias in observing or inter-
preting a scar. In this study the presence of a BCG scar was
regarded as evidence of being vaccinated and was considered
a reliable way of identifying whether patients received the
vaccine or not.17 Those with doubtful scar information were
considered as lacking a BCG scar. Our decision to consider
patients with doubtful scar information as having no scar did
not inﬂuence the outcome, as analysis with or without inclusion
of such patients did not change the signiﬁcant association of the
presence of a BCG scar with sputum culture conversion.
The BCG vaccine is still the only vaccine in use against TB, but
efforts to develop new vaccines are in progress.18 Despite the BCG
vaccine being in use for over 80 years, itsmechanism of protection
in humans is not well understood although, in the mouse model
of TB, BCG vaccination tends to reduce the bacillary burden and
dissemination.19 Apart from the protection that BCG confers
against severe forms of childhood TB, it has been suggested that
BCG vaccination may have a non-speciﬁc beneﬁcial effect on
childhood survival.20 21 In BCG-vaccinated children in Guinea-
Bissau a BCG scar was related to better child survival and in
a hospital study from Malawi a BCG scar was related to fewer
skin infections and less sepsis.18 22 A meta-analysis of BCG trials
has reported that the protective efﬁcacy of the vaccine varies
across populations, ranging from 0% to 80%.6 23 A meta-analysis
of BCG trial data also suggests that the protective efﬁcacy of BCG
may persist for $10 years after infant vaccination.24 A study by
Weir et al showed that BCG vaccination during infancy and
adolescence can induce immunological memory to mycobacterial
antigens that is measurable up to 14 years.25 Additionally, recent
studies of the long-term efﬁcacy of BCG vaccination show that,
among American Indians and Alaska natives, protection could
last up to 60 years26 and for up to 20 years in Brazilians vacci-
nated as neonates.27 Studies in BCG-vaccinated and unvaccinated
individuals who develop TB followed up to the 2-month obser-
vation point are needed to identify potential biomarkers associ-
ated with early sputum conversion.
In conclusion, this study shows that initial (pretreatment)
high culture grading is a risk factor for sputum culture non-
conversion. Interestingly, the presence of a BCG scar is signiﬁ-
cantly associated with culture conversion at the end of the
intensive phase of anti-TB treatment. This novel ﬁnding needs
to be conﬁrmed in larger studies in Tanzania as well as in other
geographical locations and populations. While waiting for a new
effective TB vaccine, we should not forget the beneﬁt that the
existing vaccine (BCG) may convey.
Table 2 Predictors of sputum culture non-conversion for 546 patients with pulmonary tuberculosis who were sputum culture positive at baseline and
followed up at the end of the second month of intensive phase treatment
All
(N[546)
Converted
(N[516)
Not converted
(N[30) p Value
Crude OR
(95% CI) for
non-conversion p Value
Adjusted* OR
(95% CI) for
non-conversion p Value
Age (years) (N¼546)
15e24 103 95 (92.2%) 8 (7.8%) 0.31 2.13 (0.77 to 5.84) 0.14 2.09 (0.76 to 5.77) 0.15
25e34 210 202 (96.2%) 8 (3.8%) 1.0 1.0
35e44 234 124 (92.5%) 10 (7.5%) 2.04 (0.78 to 5.30) 0.15 1.83 (0.70 to 4.80) 0.22
$45 99 95 (96.0%) 4 (4.0%) 1.06 (0.31 to 3.62) 0.92 2.00 (0.83 to 4.82) 0.87
Sex (N¼546)
Female 201 194 (96.5%) 7 (3.5%) 0.12 1.0 1.0
Male 345 322 (93.3%) 23 (6.7%) 1.98 (0.83 to 4.70) 0.12 2.00 (0.83 to 4.82) 0.12
Smoking (N¼543)
Never 351 336 (95.7%) 15 (4.3%) 0.20 1.0 1.0
Past 55 50 (90.9%) 5 (9.1%) 2.24 (0.78 to 6.43) 0.13 2.18 (0.69 to 6.82) 0.18
Current 137 127 (92.7%) 10 (7.3%) 1.76 (0.77 to 4.03) 0.18 1.69 (0.66 to 4.32) 0.27
Culture grading (N¼546)y
#2+ 157 155 (98.7%) 2 (1.3%) 0.006 1.0 1.0
3+ 389 361 (92.8%) 28 (7.2%) 6.01 (1.41 to 25.54) 0.02 5.70 (1.34 to 24.31) 0.02
BCG scar (N¼539)
Present 444 426 (96.0%) 18 (4.1%) 0.003 1.0 1.0
Not present 95 84 (88.4%) 11 (11.6%) 3.10 (1.41 to 6.80) 0.005 3.35 (1.48 to 7.58) 0.004
CD4 (cells/ml) (N¼546)
<200 122 117 (95.9%) 5 (4.1%) 1.0 1.0
201e350 136 126 (92.7%) 10 (7.4%) 0.50 1.86 (0.62 to 5.59) 0.27 1.86 (0.61 to 5.68) 0.28
>351 288 273 (94.8%) 15 (5.2%) 1.29 (0.46 to 3.62) 0.63 1.16 (0.40 to 3.36) 0.79
HIV status (N¼546)
Negative 330 310 (93.9%) 20 (6.1%) 0.47 1.0 1.0
Positive 216 206 (95.4%) 10 (4.6%) 0.75 (0.35 to 1.64) 0.47 0.87 (0.39 to 1.96) 0.74
Anaemia (N¼546)z
Not present 117 109 (93.2%) 8 (6.8%) 0.47 1.0 1.0 0.61
Present 429 407 (94.9%) 22 (5.1%) 0.74 (0.32 to 1.70) 0.47 0.80 (0.34 to 1.87)
BMI (kg/m2) (N¼546)
$18.5 227 218 (96.0%) 9 (4.0%) 0.24 1.0 1.0
17.0e18.5 135 124 (91.9%) 11 (8.2%) 1.39 (0.55 to 3.50) 0.48 1.32 (0.52 to 3.37) 0.56
<17.0 184 174 (94.6%) 10 (5.4%) 2.15 (0.87 to 5.33) 0.10 1.86 (0.73 to 4.70) 0.19
*Adjusted for age and sex.
yCulture grading defined as: #2+, 1e>100 non-confluent colonies; 3+, confluent colonies.
zAnaemia defined as haemoglobin <12.0 g/dl for women and <13.0 g/dl for men.
BCG, Bacillus Calmette-Gue´rin; BMI, body mass index.
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